Medical Developments International Limited announced on 6 December 2019 that the Russian Ministry of Health has accepted MVP's Marketing Authorisation Application (MAA) for review. MVP submitted the MAA for Penthrox on 30 September and after a two-month validation period, the Russian Ministry of Health advised that the Penthrox MAA had been accepted. At this stage MVP has been advised that no further clinical work is required in Russia and that the Ministry of Health intend to review the same "Clinical, Safety and Efficacy" data, which MVP used to support the approval of Penthrox in Europe and elsewhere. MVP's application to the Ministry of Health is for Penthrox to be approved for Trauma Pain. The Penthrox MAA was submitted under the new unified Eurasian Economic Union (EAEU) rules. The EAEU rules means MVP's application is for Penthrox to be approved for sale in Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan. The review process and final approval in Russia is expected within 15 months and the remaining countries are expected within 2 years. The acceptance of the MAA triggers a milestone payment from Russian partner.